NCT02004522 2023-09-21
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
SecuraBio
Phase 3 Completed
Clinical Trials
10 trialsNCT02049515 2023-09-21
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
SecuraBio
Phase 3 Completed
NCT01077518 2020-03-27
A+B
Novartis
Phase 3 Terminated
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed
NCT01659021 2019-08-14
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01039376 2019-07-30
PROLONG
Novartis
Phase 3 Terminated
NCT00748189 2019-06-25
COMPLEMENT 1
Novartis
Phase 3 Terminated
NCT01200589 2018-05-16
HOMER
Novartis
Phase 3 Terminated
NCT01580228 2017-02-23
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01014208 2015-08-07
ORCHARRD
GlaxoSmithKline
Phase 3 Completed